Synthetic lethality and context-selective DNA-damage response dependencies: from genetic vulnerability to pharmacological translation.

Authors

Nayoon Jo, Su-Jin Kang, Jeongeun Kim, Kwan Hyi Lee, Sunbok Jang

Published in

Drug discovery today. Pages 104803. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

Synthetic lethality has established DNA-damage response (DDR) dependencies as a major strategy for precision cancer therapy, exemplified by targeting BRCA1/2 and poly(ADP-ribose) polymerase (PARP). However, genetic dependency alone does not ensure pharmacological tractability or clinical utility. Emerging targets, including WRN, POLQ, USP1 and PARG, impose distinct requirements for ligandability, selectivity, target engagement, patient selection and the therapeutic window. A comparison of their structural biology, inhibitor chemotypes, SAR, pharmacodynamic strategies, resistance mechanisms and clinical development shows that successful translation requires matching a tumor-selective dependency to an experimentally validated, exposure-controllable pharmacological mechanism. This framework supports the rational prioritization of context-selective DDR dependencies beyond BRCA-PARP.

PMID:
42727625
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.